Gracell Biotechnologies Stock News

Gainers US Ecology, Inc. (NASDAQ: ECOL ) shares jumped 68.1% to $47.34 after Republic Services reported it will buy the company at $48 per share in cash. Tritium DCFC Limited (NASDAQ: DCFC ) gained 65.4% to $15.78. Tritium DCFC shares surged nearly 40% Tuesday after the Australian EV charging company announced its new manufacturing facility will be located in the United States. Tritium CEO Jane Hunter appeared at the White House to make the announcement yesterday. Infobird Co., Ltd (NASDAQ: IFBD ) gained 32.6% to $1.2393. Infobird recently signed a contract with subsidiary of Nippi Japan for digital marketing solutions. Doximity, Inc. (NYSE: DOCS ) shares gained 25.1% to $62.30 after the company reported better-than-expected Q3 results and issued FY22 sales guidance above estimates. Aptevo Therapeutics Inc. (NASDAQ: APVO ) jumped 20.5% to $7.29 after the company announced it has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE. Absolute Software Corporation (NASDAQ: ABST ) gained 17.9% to $9.47 after the company reported better-than-expected Q2 sales results and issued FY22 sales guidance.

Gracell Biotechnologies Inc - ADR (GRCL) shares closed today 10.8% lower than it did at the end of yesterday. The stock is currently down 13.9% year-to-date, down 79.2% over the past 12 months, and down 79.2% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $6.60 and as low as $5.07 this week.Shares closed 86.2% below its 52-week high and 8.5% below its 52-week low.Trading volume this week was 33.1% higher than the 10-day average and 1.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1106.6% The company's stock price performance over the past 12 months lags the peer average by 1216.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Gracell Biotechnologies Inc - ADR (GRCL) shares closed 8.5% lower than its previous 52 week low, giving the company a market cap of $350M. The stock is currently down 13.9% year-to-date, down 79.2% over the past 12 months, and down 79.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 1.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1106.6% The company's stock price performance over the past 12 months lags the peer average by 1216.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Gracell Biotechnologies Inc - ADR (GRCL) shares closed today at 2.0% above its 52 week low of $5.54, giving the company a market cap of $381M. The stock is currently down 77.5% year-to-date, down 77.5% over the past 12 months, and down 77.5% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 71.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1056.5% The company's stock price performance over the past 12 months lags the peer average by 907.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Gracell Biotechnologies Inc. (NASDAQ:GRCL)s share price shot up 4.1% during mid-day trading on Tuesday . The stock traded as high as $7.62 and last traded at $7.55. 11,899 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,232,226 shares. The stock had previously closed at $7.25. Separately, Zacks []

In last trading session, Gracell Biotechnologies Inc. (NASDAQ:GRCL) saw 1.06 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $6.87 trading at -$0.87 or -11.24% at ring of the bell on the day assigns it a market valuation of $469.77M. That closing price of GRCLs stock is How To Know If Gracell Biotechnologies Inc. (NASDAQ:GRCL) Is Expensive At $6.87. Read More »

During the last session, Gracell Biotechnologies Inc. (NASDAQ:GRCL)s traded shares were 1.55 million. At the end of the trading day, the stocks price was $7.09, reflecting an intraday loss of -8.99% or -$0.7. The 52-week high for the GRCL share is $33.70, that puts it down -375.32 from that peak though still a striking 17.35% Gracell Biotechnologies Inc. (NASDAQ: GRCL) Is Down -32.48% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

In today’s recent session, 5.72 million shares of the Gracell Biotechnologies Inc. (NASDAQ:GRCL) were traded. Most recently the company’s share price was $11.45, and it changed around $5.07 or 79.47% from the last close, which brings the market valuation of the company to $436.26M. GRCL at last check was trading at a discount to its … Gracell Biotechnologies Inc. (NASDAQ: GRCL): How It Has Performed & Trended Read More »

The stock price of Gracell Biotechnologies Inc (NASDAQ: GRCL) increased by over 70% during intraday trading today. This is why it happened.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) has reported that the U.S. FDA has granted Orphan Drug Destination for GC012F, Gracells FasTCARE-enabled BCMA/CD19 dual targeting CAR-T cell therapy for treatment of multiple myeloma. As our lead candidate currently being developed on Gracells FasTCAR next-day manufacturing technology platform, GC012F is a unique BCMA and CD19 dual-targeting CAR-T cell The post Gracell Biotechnologies Granted FDA Drug Destination to Treat Multiple Myeloma first appeared on Financial Buzz .

Marshall Wace North America L.P. trimmed its position in shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL) by 1.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 82,369 shares of the companys stock after selling 1,191 shares during the quarter. Marshall Wace North America L.P.s holdings in Gracell Biotechnologies were worth $1,070,000 as of its most []

Gracell Biotechnologies Inc. (NASDAQ:GRCL)s share price reached a new 52-week low during trading on Friday . The stock traded as low as $8.27 and last traded at $8.98, with a volume of 240168 shares changing hands. The stock had previously closed at $11.53. Separately, Zacks Investment Research downgraded Gracell Biotechnologies from a hold rating to []

Gracell Biotechnologies Inc. (NASDAQ:GRCL) dropped 13.3% during trading on Thursday . The company traded as low as $10.00 and last traded at $10.00. Approximately 1,436 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 128,372 shares. The stock had previously closed at $11.53. Separately, Zacks Investment Research cut []